Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Pivotal Study Assessing the Efficacy and Safety of 15 mg Twice a Day (BID) of SER150 in Well-controlled Type 2 Diabetic Patients With Diabetic Kidney Disease and Macroalbuminuria in Treatment With an Angiotensin Converting Enzyme Inhibitor or an Angiotensin Receptor Antagonist
Latest Information Update: 24 Jun 2024
At a glance
- Drugs SER 150 (Primary)
- Indications Diabetic nephropathies
- Focus Registrational; Therapeutic Use
- Sponsors Serodus
- 20 Jun 2024 Status changed from recruiting to completed.
- 02 Nov 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 100 to 110, time frame of primary endpoint changed from Baseline, Day 84 to Baseline, Day 84 and Day 168.
- 02 Nov 2022 Planned number of patients changed from 100 to 110.